GlassScriptPhysician profile
Moises Adrian Sidransky
NPI 1639469281
$6,459.88
in general payments reported to CMS, 2019-2025
28 companies · $815 in 2025
The $815 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,375 · 2020: $432 · 2021: $278 · 2022: $380 · 2023: $373 · 2024: $1,808 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099 · Travel and Lodging: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.89 |
| Travel and Lodging | $896.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,363.10 | 2019-2024 | Senza |
| Curonix LLC | $1,108.87 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbott Laboratories | $888.04 | 2019-2024 | Eterna, Prodigy |
| Abbvie INC. | $407.23 | 2022-2025 | Botox |
| Nalu Medical, INC. | $327.52 | 2024-2025 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $193.98 | 2021-2025 | Wavewriter Alpha Prime 16, General - Therapies, Na |
| Collegium Pharmaceutical, INC. | $168.03 | 2023-2025 | Belbuca, Xtampza, Nucynta |
| Globus Medical, INC. | $136.81 | 2025 | Senza |
| Amgen INC. | $107.55 | 2020-2022 | |
| Bioventus LLC | $96.98 | 2019-2023 | Durolane |
| Medtronic USA, INC. | $92.11 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $73.04 | 2025 | |
| Allergan, INC. | $60.22 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $55.79 | 2021-2024 | |
| Spr Therapeutics, INC | $48.00 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals LLC | $46.78 | 2025 | Trudhesa |
| Lundbeck LLC | $43.92 | 2022-2023 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $43.45 | 2022 | |
| Amneal Pharmaceuticals LLC | $33.65 | 2023 | Lyvispah |
| Kowa Pharmaceuticals America, INC. | $32.36 | 2023 | Seglentis |
| Siemens Medical Solutions USA, INC. | $23.27 | 2025 | Cios Flow |
| Painteq LLC | $18.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.01 | 2021 | |
| Medtronic, INC. | $17.62 | 2025 | Inceptiv |
| Forte Bio-Pharma LLC | $14.74 | 2024 | Prolate, Nalocet |
| Biohaven Pharmaceutical Holding Company LTD. | $14.72 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Sidransky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.